Sympathetic nervous activation in obesity and the metabolic syndrome-Causes, consequences and therapeutic implications

Gavin W. Lambert, Nora E. Straznicky, Elisabeth A. Lambert, John B. Dixon, Markus P. Schlaich

Research output: Contribution to journalReview article

207 Citations (Scopus)

Abstract

The world wide prevalence of obesity and the metabolic syndrome is escalating. Contrary to earlier experimental evidence, human obesity is characterised by sympathetic nervous activation, with the outflows to both the kidney and skeletal muscle being activated. While the mechanisms responsible for initiating the sympathetic activation remain to be unequivocally elucidated, hyperinsulinemia, obstructive sleep apnoea, increased circulating adipokines, stress and β adrenergic receptor polymorphisms are implicated. The pattern of sympathetic activation may be the pathophysiological mechanism underpinning much obesity-related illnesses with the consequences including, amongst others, the development of hypertension, insulin resistance, diastolic dysfunction and renal impairment. While diet and exercise are the first line therapy for the treatment of obesity and the metabolic syndrome, pharmacological interventions targeting the sympathetic nervous system, either directly or indirectly are also likely to be of benefit. Importantly, the benefit may not necessarily be weight related but may be associated with a reduction in end organ damage.

Original languageEnglish
Pages (from-to)159-172
Number of pages14
JournalPharmacology and Therapeutics
Volume126
Issue number2
DOIs
Publication statusPublished - 1 May 2010
Externally publishedYes

Fingerprint

Obesity
Kidney
Adipokines
Sympathetic Nervous System
Hyperinsulinism
Obstructive Sleep Apnea
Therapeutics
Adrenergic Receptors
Insulin Resistance
Skeletal Muscle
Pharmacology
Diet
Hypertension
Weights and Measures

Cite this

Lambert, Gavin W. ; Straznicky, Nora E. ; Lambert, Elisabeth A. ; Dixon, John B. ; Schlaich, Markus P. / Sympathetic nervous activation in obesity and the metabolic syndrome-Causes, consequences and therapeutic implications. In: Pharmacology and Therapeutics. 2010 ; Vol. 126, No. 2. pp. 159-172.
@article{676ce53786e44c87ba0d48b9c13b372e,
title = "Sympathetic nervous activation in obesity and the metabolic syndrome-Causes, consequences and therapeutic implications",
abstract = "The world wide prevalence of obesity and the metabolic syndrome is escalating. Contrary to earlier experimental evidence, human obesity is characterised by sympathetic nervous activation, with the outflows to both the kidney and skeletal muscle being activated. While the mechanisms responsible for initiating the sympathetic activation remain to be unequivocally elucidated, hyperinsulinemia, obstructive sleep apnoea, increased circulating adipokines, stress and β adrenergic receptor polymorphisms are implicated. The pattern of sympathetic activation may be the pathophysiological mechanism underpinning much obesity-related illnesses with the consequences including, amongst others, the development of hypertension, insulin resistance, diastolic dysfunction and renal impairment. While diet and exercise are the first line therapy for the treatment of obesity and the metabolic syndrome, pharmacological interventions targeting the sympathetic nervous system, either directly or indirectly are also likely to be of benefit. Importantly, the benefit may not necessarily be weight related but may be associated with a reduction in end organ damage.",
keywords = "Metabolic syndrome, Microneurography, Overweight, Sympathetic nervous system, Target organ damage",
author = "Lambert, {Gavin W.} and Straznicky, {Nora E.} and Lambert, {Elisabeth A.} and Dixon, {John B.} and Schlaich, {Markus P.}",
year = "2010",
month = "5",
day = "1",
doi = "10.1016/j.pharmthera.2010.02.002",
language = "English",
volume = "126",
pages = "159--172",
journal = "Pharmacology & Therapeutics",
issn = "0163-7258",
publisher = "Elsevier",
number = "2",

}

Sympathetic nervous activation in obesity and the metabolic syndrome-Causes, consequences and therapeutic implications. / Lambert, Gavin W.; Straznicky, Nora E.; Lambert, Elisabeth A.; Dixon, John B.; Schlaich, Markus P.

In: Pharmacology and Therapeutics, Vol. 126, No. 2, 01.05.2010, p. 159-172.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Sympathetic nervous activation in obesity and the metabolic syndrome-Causes, consequences and therapeutic implications

AU - Lambert, Gavin W.

AU - Straznicky, Nora E.

AU - Lambert, Elisabeth A.

AU - Dixon, John B.

AU - Schlaich, Markus P.

PY - 2010/5/1

Y1 - 2010/5/1

N2 - The world wide prevalence of obesity and the metabolic syndrome is escalating. Contrary to earlier experimental evidence, human obesity is characterised by sympathetic nervous activation, with the outflows to both the kidney and skeletal muscle being activated. While the mechanisms responsible for initiating the sympathetic activation remain to be unequivocally elucidated, hyperinsulinemia, obstructive sleep apnoea, increased circulating adipokines, stress and β adrenergic receptor polymorphisms are implicated. The pattern of sympathetic activation may be the pathophysiological mechanism underpinning much obesity-related illnesses with the consequences including, amongst others, the development of hypertension, insulin resistance, diastolic dysfunction and renal impairment. While diet and exercise are the first line therapy for the treatment of obesity and the metabolic syndrome, pharmacological interventions targeting the sympathetic nervous system, either directly or indirectly are also likely to be of benefit. Importantly, the benefit may not necessarily be weight related but may be associated with a reduction in end organ damage.

AB - The world wide prevalence of obesity and the metabolic syndrome is escalating. Contrary to earlier experimental evidence, human obesity is characterised by sympathetic nervous activation, with the outflows to both the kidney and skeletal muscle being activated. While the mechanisms responsible for initiating the sympathetic activation remain to be unequivocally elucidated, hyperinsulinemia, obstructive sleep apnoea, increased circulating adipokines, stress and β adrenergic receptor polymorphisms are implicated. The pattern of sympathetic activation may be the pathophysiological mechanism underpinning much obesity-related illnesses with the consequences including, amongst others, the development of hypertension, insulin resistance, diastolic dysfunction and renal impairment. While diet and exercise are the first line therapy for the treatment of obesity and the metabolic syndrome, pharmacological interventions targeting the sympathetic nervous system, either directly or indirectly are also likely to be of benefit. Importantly, the benefit may not necessarily be weight related but may be associated with a reduction in end organ damage.

KW - Metabolic syndrome

KW - Microneurography

KW - Overweight

KW - Sympathetic nervous system

KW - Target organ damage

UR - http://www.scopus.com/inward/record.url?scp=77951091946&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2010.02.002

DO - 10.1016/j.pharmthera.2010.02.002

M3 - Review article

VL - 126

SP - 159

EP - 172

JO - Pharmacology & Therapeutics

JF - Pharmacology & Therapeutics

SN - 0163-7258

IS - 2

ER -